MarketStudyReport.com adds “Global Dalteparin Sodium Market Outlook 2016-2021” new report to its research database. The report spread across 106 pages with table and figures in it.
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin by Pfizer Inc. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism. It is normally administered by self-injection.
The CLOT study, published in 2003, showed that in patients with malignancy and acute venous thromboembolism, dalteparin was more effective than warfarin in reducing the risk of recurrent embolic events. Dalteparin is not superior to unfractionated heparin in preventing blood clots.
Heparins are cleared by the kidneys, but studies have shown that dalteparin does not accumulate even if kidney function is reduced.
Browse full table of contents and data tables @ https://www.marketstudyreport.com/reports/global-dalteparin-sodium-market-outlook-2016-2021/
This report provides detailed analysis of worldwide markets for Dalteparin Sodium from 2011-2015 and provides extensive market forecasts 2016-2021 by region/country and subsectors. It covers the key technological and market trends in the Dalteparin Sodium market and further lays out an analysis of the factors influencing the supply/demand for Dalteparin Sodium, and the opportunities/challenges faced by industry participants. It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Global Dalteparin Sodium Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of information about the global Dalteparin Sodium market collected from specialized sources. The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players. The major players in the global Dalteparin Sodium market are Pfizer (USA), Reliable Biopharmaceutical (USA), Gland Pharma (India), Opocrin (Italy), Hebei Changshan (China), Changzhou Qianhong (China), Nanjing Kingfriend (China), among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Dalteparin Sodium industry has been provided.
To receive personalized assistance, write to us @ firstname.lastname@example.org with the report title in the subject line along with your questions or call us at +1 866-764-2150